Baidu
map

国家中医药局学习党的十九大精神培训班开班:牢记使命,扎实传承发展中医药

2017-11-17 韩静 中国中医

11月16日,国家中医药管理局学习党的十九大精神培训班在中国中医科学院东区会议中心开班。国家卫生计生委副主任,国家中医药管理局党组书记、局长王国强作动员报告指出,要紧密结合中医药工作实际,推进十九大的重大决策部署落到实处、取得实效。国家中医药管理局党组成员、副局长闫树江主持开班仪式。

11月16日,国家中医药管理局学习党的十九大精神培训班在中国中医科学院东区会议中心开班。国家卫生计生委副主任,国家中医药管理局党组书记、局长王国强作动员报告指出,要紧密结合中医药工作实际,推进十九大的重大决策部署落到实处、取得实效。国家中医药管理局党组成员、副局长闫树江主持开班仪式。

此次培训班是国家中医药管理局党组按照中央的要求组织的,旨在对国家中医药管理局学习宣传贯彻党的十九大精神进行部署动员,切实把直属机关各级党组织和广大党员干部的思想统一到党的十九大精神上来,把智慧和力量凝聚到实现党的十九大确定的各项任务上来。

王国强要求,国家中医药管理局直属机关各级党组织和广大党员干部要锐意进取,毫不松懈,扎实做好“传承发展中医药事业”的各项工作。各单位各部门要以党的十九大精神为指导,把学习党的十九大精神与学习贯彻习近平总书记在全国卫生与健康大会上的重要讲话结合起来,党的十九大报告就“实施健康中国战略”提出了全面部署,并明确了“坚持中西医并重,传承发展中医药事业”的战略部署,各单位各部门要全面落实党的十九大对中医药工作的要求。

王国强指出,一要以人民健康为中心, 持续推动中医药振兴发展。要始终坚持新形势下卫生与健康工作方针,既要在完善国民健康政策中作出有效的制度设计和安排,为人民群众提供全方位全周期的中医药健康服务;又要在深化医药卫生体制改革中发挥中医药的独特优势,坚持中西医并重,构建中国特色社会主义的五项基本医疗卫生制度建设,保障好人民群众的基本健康权益。要准确把握党中央作出“两个阶段”重大战略安排带来的机遇和条件的变化,推动中医药各项工作向党的十九大作出的“两个阶段”的重大战略安排来谋划,向聚焦“两个一百年”奋斗目标来摆布,不断理清发展思路,完善发展举措,科学确定中医药的发展目标,确保中医药工作与党和国家的中心工作步调一致、目标明确、战略协调。

二要以推进中医药供给侧结构性改革为主线,不断激发和释放中医药“五种资源”的活力和潜力。要把握我国社会主要矛盾变化对中医药工作提出的新要求,主动顺应人民群众对中医药健康服务更加多元和更高的需求,以发展质量和效益为中心,推进中医药领域的深化改革,扩大中医药健康服务供给,保障人民群众享有中医药服务的权益。要大力激发和释放中医药“五种资源”的活力和潜力。在卫生与健康领域,要按照全国卫生与健康大会的工作部署,完善中医药服务体系,优化中医药健康服务,完善中医药健康保障,发展中医药健康产业。在经济领域,要全链条、全环节、全要素开发我国丰富的中医药资源,大力发展中医药健康产业,拉长产业链,促进大融合,发展新业态,为经济快速增长“固本培元”“壮筋续骨”。在科技领域,要立足服务创新性国家建设,把科技创新摆在中医药发展的核心位置,坚持中医药原创思维和理论自信,突出中医药特色和优势,推进中医药的传承与创新。在文化领域,一方面要保护好老祖宗留给我们的宝库,另一方面要坚持古为今用,努力实现中医药健康养生文化的创造性转化、创新性发展,使藏在古籍、用在临床、融入生活的中医药健康理念、方法和技术更好地服务人民健康。在生态领域,一方面要大力倡导中医药蕴含的自然生态观念,引导人们尊重生命、顺应自然、热爱自然;另一方面要加强中药材保护和利用,充分发挥中药材种植在生物多样性保护、生态安全屏障、荒漠化治理、精准脱贫中的作用,在还生态以自然美丽中提升中药材的供给和保障水平。

国家中医药管理局机关及直属单位(不含中国中医科学院)处级以上领导干部、中国中医科学院及二级院所领导班子成员、国家中医药管理局社会组织党委处级以上领导干部、国家中医药管理局各直属单位基层党支部书记参加培训班。

培训班为期两天,将通过开展专题报告、收看学习宣传片、分组讨论学习体会等形式深入学习宣传贯彻党的十九大精神。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1708183, encodeId=1b9e1e0818306, content=<a href='/topic/show?id=bd5226e986d' target=_blank style='color:#2F92EE;'>#使命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26798, encryptionId=bd5226e986d, topicName=使命)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21a31549739, createdName=ms920641618706883, createdTime=Sun Apr 22 04:24:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978070, encodeId=d13b19e80709d, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Apr 18 16:24:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077161, encodeId=05dd20e71616b, content=<a href='/topic/show?id=af892152021' target=_blank style='color:#2F92EE;'>#中医药局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21520, encryptionId=af892152021, topicName=中医药局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sat Jan 06 15:24:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675555, encodeId=76de16e555594, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Feb 22 02:24:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636290, encodeId=9f4b1636290ed, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Mon May 21 03:24:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262586, encodeId=8d8026258640, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Nov 19 14:45:46 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409192, encodeId=8d621409192f3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Nov 19 08:24:00 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1708183, encodeId=1b9e1e0818306, content=<a href='/topic/show?id=bd5226e986d' target=_blank style='color:#2F92EE;'>#使命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26798, encryptionId=bd5226e986d, topicName=使命)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21a31549739, createdName=ms920641618706883, createdTime=Sun Apr 22 04:24:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978070, encodeId=d13b19e80709d, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Apr 18 16:24:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077161, encodeId=05dd20e71616b, content=<a href='/topic/show?id=af892152021' target=_blank style='color:#2F92EE;'>#中医药局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21520, encryptionId=af892152021, topicName=中医药局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sat Jan 06 15:24:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675555, encodeId=76de16e555594, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Feb 22 02:24:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636290, encodeId=9f4b1636290ed, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Mon May 21 03:24:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262586, encodeId=8d8026258640, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Nov 19 14:45:46 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409192, encodeId=8d621409192f3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Nov 19 08:24:00 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1708183, encodeId=1b9e1e0818306, content=<a href='/topic/show?id=bd5226e986d' target=_blank style='color:#2F92EE;'>#使命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26798, encryptionId=bd5226e986d, topicName=使命)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21a31549739, createdName=ms920641618706883, createdTime=Sun Apr 22 04:24:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978070, encodeId=d13b19e80709d, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Apr 18 16:24:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077161, encodeId=05dd20e71616b, content=<a href='/topic/show?id=af892152021' target=_blank style='color:#2F92EE;'>#中医药局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21520, encryptionId=af892152021, topicName=中医药局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sat Jan 06 15:24:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675555, encodeId=76de16e555594, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Feb 22 02:24:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636290, encodeId=9f4b1636290ed, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Mon May 21 03:24:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262586, encodeId=8d8026258640, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Nov 19 14:45:46 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409192, encodeId=8d621409192f3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Nov 19 08:24:00 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1708183, encodeId=1b9e1e0818306, content=<a href='/topic/show?id=bd5226e986d' target=_blank style='color:#2F92EE;'>#使命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26798, encryptionId=bd5226e986d, topicName=使命)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21a31549739, createdName=ms920641618706883, createdTime=Sun Apr 22 04:24:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978070, encodeId=d13b19e80709d, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Apr 18 16:24:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077161, encodeId=05dd20e71616b, content=<a href='/topic/show?id=af892152021' target=_blank style='color:#2F92EE;'>#中医药局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21520, encryptionId=af892152021, topicName=中医药局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sat Jan 06 15:24:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675555, encodeId=76de16e555594, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Feb 22 02:24:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636290, encodeId=9f4b1636290ed, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Mon May 21 03:24:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262586, encodeId=8d8026258640, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Nov 19 14:45:46 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409192, encodeId=8d621409192f3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Nov 19 08:24:00 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
    2018-02-22 lishizhe
  5. [GetPortalCommentsPageByObjectIdResponse(id=1708183, encodeId=1b9e1e0818306, content=<a href='/topic/show?id=bd5226e986d' target=_blank style='color:#2F92EE;'>#使命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26798, encryptionId=bd5226e986d, topicName=使命)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21a31549739, createdName=ms920641618706883, createdTime=Sun Apr 22 04:24:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978070, encodeId=d13b19e80709d, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Apr 18 16:24:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077161, encodeId=05dd20e71616b, content=<a href='/topic/show?id=af892152021' target=_blank style='color:#2F92EE;'>#中医药局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21520, encryptionId=af892152021, topicName=中医药局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sat Jan 06 15:24:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675555, encodeId=76de16e555594, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Feb 22 02:24:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636290, encodeId=9f4b1636290ed, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Mon May 21 03:24:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262586, encodeId=8d8026258640, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Nov 19 14:45:46 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409192, encodeId=8d621409192f3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Nov 19 08:24:00 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1708183, encodeId=1b9e1e0818306, content=<a href='/topic/show?id=bd5226e986d' target=_blank style='color:#2F92EE;'>#使命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26798, encryptionId=bd5226e986d, topicName=使命)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21a31549739, createdName=ms920641618706883, createdTime=Sun Apr 22 04:24:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978070, encodeId=d13b19e80709d, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Apr 18 16:24:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077161, encodeId=05dd20e71616b, content=<a href='/topic/show?id=af892152021' target=_blank style='color:#2F92EE;'>#中医药局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21520, encryptionId=af892152021, topicName=中医药局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sat Jan 06 15:24:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675555, encodeId=76de16e555594, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Feb 22 02:24:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636290, encodeId=9f4b1636290ed, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Mon May 21 03:24:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262586, encodeId=8d8026258640, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Nov 19 14:45:46 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409192, encodeId=8d621409192f3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Nov 19 08:24:00 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
    2017-11-19 1e145228m78(暂无匿称)

    学习了谢谢作者分享!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1708183, encodeId=1b9e1e0818306, content=<a href='/topic/show?id=bd5226e986d' target=_blank style='color:#2F92EE;'>#使命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26798, encryptionId=bd5226e986d, topicName=使命)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21a31549739, createdName=ms920641618706883, createdTime=Sun Apr 22 04:24:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978070, encodeId=d13b19e80709d, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Apr 18 16:24:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077161, encodeId=05dd20e71616b, content=<a href='/topic/show?id=af892152021' target=_blank style='color:#2F92EE;'>#中医药局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21520, encryptionId=af892152021, topicName=中医药局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sat Jan 06 15:24:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675555, encodeId=76de16e555594, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Feb 22 02:24:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636290, encodeId=9f4b1636290ed, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Mon May 21 03:24:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262586, encodeId=8d8026258640, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Nov 19 14:45:46 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409192, encodeId=8d621409192f3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Nov 19 08:24:00 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
    2017-11-19 cathymary

相关资讯

国家中医药局:推动十九大精神在中医药系统扎根开花结果

会议指出,十九大报告作出“坚持中西医并重,传承发展中医药事业”的重要部署,充分体现了以习近平同志为核心的党中央对中医药发展的高度重视,为我们在新时代推动中医药振兴发展提供了遵循、指明了方向。我们倍感振奋、深受鼓舞,更加感到任务艰巨、使命光荣。

国家中医药局直属机关党纪委支部进一步学习贯彻十九大精神

10月30日,国家中医药管理局直属机关党纪委支部召开支部党员大会,进一步学习党的十九大精神。会上,国家中医药管理局副局长、机关党委书记闫树江强调,十九大的最大亮点和最重要的历史贡献,是确立了习近平新时代中国特色社会主义思想的历史地位,实现了党的指导思想又一次与时俱进。党纪委支部全体同志要深入学习领会习近平新时代中国特色社会主义思想的时代背景、科学体系,深入学习领会习近平新时代中国特色社会主义思想的

国家中医药局2017年新闻宣传工作协调会议:围绕主旋律,传播正能量

10月13日,国家中医药管理局2017年新闻宣传工作协调会议召开。会议回顾总结了2017年前三季度中医药新闻宣传工作情况,并就做好下一步新闻宣传工作进行交流讨论,提出建议。国家中医药管理局副局长马建中肯定了今年以来中医药新闻宣传工作取得的成果,强调要进一步提升对新闻宣传工作重要性认识的高度,中医药事业是社会主义事业的组成部分,中医药新闻宣传要注重意识形态问题,要围绕主旋律,传播正能量。

Baidu
map
Baidu
map
Baidu
map